Healthcare / BiotechnologyUpdated 2026-05-10 22:07 UTC

LXRX stock hub

Lexicon Pharmaceuticals, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LXRXis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

847.4M

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

LXRX

In the news

Latest news · LXRX

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.3P50 18.4P75 33.1

Trailing P/En/a

P25 14.9P50 23.2P75 38.5

ROE-16

P25 -105.6P50 -46.5P75 -3.1

ROIC-6.3

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LXRX market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

196

Groups with data

Currency

USD

Showing 196 of 196 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001062822
Company name	Lexicon Pharmaceuticals, Inc.
Country	United States
Country code	US
Cusip	528872302
Employees	81
Employees Change	-22%
Employees Change Percent	-21.36
Enterprise value	$726.4M
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Biotechnology
IPO Date	2000-04-07
Isin	US5288723027
Last refreshed	2026-05-10
Market cap	$847.4M
Market cap category	Small-Cap
Price	$2
Price currency	USD
Rev Per Employee	859,790.12x
Sector	Healthcare
Sic	2834
Symbol	LXRX
Website	https://www.lexpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-3.08%
EV Sales Forward	22.17x
EV/Sales	10.43x
P/B ratio	3.95x
P/S ratio	12.17x
PS Forward	25.86x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	-34.79%
EBITDA Margin	-33.93%
Gross margin	90.46%
Gross Profit	$63M
Net Income	$-26.1M
Net Income Growth Quarters	6%
Net Income Growth Years	1%
Pretax Margin	-37.46%
Profit Margin	-37.46%
Profit Per Employee	$-322,086
ROA	-5.35
Roa5y	-35.92
ROE	-16.01
Roe5y	-105.9
ROIC	-6.29

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	-16.56%
Cagr15y	-11%
Cagr1y	192.19%
Cagr20y	-13.46%
Cagr3y	-16.93%
Cagr5y	-15.27%
EPS Growth Years	2
Revenue Growth	123.12x
Revenue Growth Q	1,572.11x
Revenue Growth Quarters	1x
Revenue Growth Years	3x
Revenue Growth3 Y	720.67x
Revenue Growth5 Y	34.16x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.25
Assets	$268.8M
Cash	$170.7M
Current Assets	$199.7M
Debt	$49.7M
Debt Equity	$0.24
Equity	$202.9M
Interest Coverage	-2.99
Liabilities	$66M
Long Term Assets	$69.2M
Net Cash	$121M
Net Cash By Market Cap	$14.28
Net Cash Growth	36.58%
Net Debt Equity	$-0.6
Tangible Book Value	$158.3M
Tangible Book Value Per Share	$0.4
WACC	9.79

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Working Capital	$199.7M
Working Capital Turnover	$0.42

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-6.7%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	-83.63%
1Y total return	191.97%
200-day SMA	1.39
3Y total return	-42.69%
50-day SMA	1.67
50-day SMA vs 200-day SMA	50over200
5Y total return	-56.33%
All Time High	344.8
All Time High Change	-99.42%
All Time High Date	2000-07-21
All Time Low	0.28
All Time Low Change	605.22%
All Time Low Date	2025-03-03
ATR	0.12
Beta	0.97
Beta1y	-0.57
Beta2y	1.92
Ch YTD	73.91
High	2
High52	2
High52 Date	2026-05-08
High52ch	0%
Low	1.64
Low52	0.51
Low52 Date	2025-05-15
Low52ch	289.33%
Ma50ch	19.69%
Premarket Change Percent	1.19
Premarket Price	$1.7
Premarket Volume	1,231
Price vs 200-day SMA	43.99%
RSI	67.57
RSI Monthly	58.69
RSI Weekly	63.71
Sharpe ratio	1.63x
Sortino ratio	2.77
Total Return	-6.7%
Tr YTD	73.91
Tr15y	-82.58%
Tr1m	25%
Tr1w	22.7%
Tr3m	62.6%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	2
Analyst Ratings	Strong Buy
Earnings EPS Estimate	$-0.04
Earnings Revenue Estimate	9,570,952x
Earnings Revenue Estimate Growth	658.4x
Operating Income	$-24.2M
Operating margin	-34.79
Price target	$4.15
Price Target Change	$108

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	198,336,764%
Float Percent	46.81%
Shares Insiders	1.39%
Shares Institutions	21.44%
Shares Out	423,680,611
Shares Qo Q	10.13%
Shares Yo Y	6.7%
Short Float	11.94%
Short Ratio	10.17
Short Shares	5.59

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Average Volume	2,094,156.05x
Bv Per Share	0.51
Ch10y	-83.63
Ch15y	-82.58
Ch1m	25
Ch1w	22.7
Ch1y	192
Ch20y	-94.45
Ch3m	62.6
Ch3y	-42.69
Ch5y	-56.33
Ch6m	60
Change	19.05%
Change From Open	18.34
Close	1.68
Days Gap	0.6
Depreciation Amortization	600,250
Dollar Volume	14,037,468
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$-24.2M
EBITDA	$-23.6M
EPS	$-0.07
F Score	3
Fiscal Year End	December
Founded	1,995
Goodwill	44,543,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Date	2015-05-21
Last Split Type	Reverse
Last10k Filing Date	2026-03-05
Ma150	1.47
Ma150ch	36.43%
Ma20	1.73
Ma20ch	15.74%
Next Earnings Date	2026-08-05
Open	1.69
Optionable	Yes
Position In Range	100
Post Close	2
Postmarket Change Percent	-2.93
Postmarket Price	$1.94
Ppne	1,753,000
Pre Close	1.68
Price Date	2026-05-08
Ptbv Ratio	5.35
Relative Volume	3.35x
Revenue	69,643,000x
Tr20y	-94.45%
Tr6m	60%
Us State	Texas
Volume	7,018,734

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LXRX pay a dividend?

Capital-return profile for this ticker.

Performance

LXRX stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LXRX?

Insider, institutional, and short-interest positioning.

Institutional ownership

+21.4%

Float: +46.8% of shares outstanding

Insider ownership

+1.4%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

LXRX momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

67.6

Neutral momentum band

Price vs 200-day MA

+44.0%

50/200-day relationship not available

Beta (5Y)

0.97

Moves roughly with the market

Sharpe ratio

1.63

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LXRX

Hub-level FAQ points readers to the deeper analysis pages.

What is the current LXRX stock rating?

Lexicon Pharmaceuticals, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full LXRX analysis?

The full report lives at /stocks/LXRX/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for LXRX?

The latest report frames LXRX around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the LXRX page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.